These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Understanding PCSK9 and anti-PCSK9 therapies. McKenney JM J Clin Lipidol; 2015; 9(2):170-86. PubMed ID: 25911073 [TBL] [Abstract][Full Text] [Related]
47. Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9. Budha NR; Leabman M; Jin JY; Wada DR; Baruch A; Peng K; Tingley WG; Davis JD AAPS J; 2015 Jul; 17(4):881-90. PubMed ID: 25823668 [TBL] [Abstract][Full Text] [Related]
48. The promises of PCSK9 inhibition. Petrides F; Shearston K; Chatelais M; Guilbaud F; Meilhac O; Lambert G Curr Opin Lipidol; 2013 Aug; 24(4):307-12. PubMed ID: 23817198 [TBL] [Abstract][Full Text] [Related]
49. Biologics for the treatment of dyslipidemias: a look beyond conventional therapy. Yoon CH; Watson K Ann Pharmacother; 2014 Feb; 48(2):238-49. PubMed ID: 24259646 [TBL] [Abstract][Full Text] [Related]
50. Update of Clinical Trials of Anti-PCSK9 Antibodies. Wu NQ; Li S; Li JJ Cardiovasc Drugs Ther; 2015 Apr; 29(2):159-69. PubMed ID: 25916406 [TBL] [Abstract][Full Text] [Related]
51. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction. Tavori H; Melone M; Rashid S Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623 [TBL] [Abstract][Full Text] [Related]
52. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Joseph L; Robinson JG Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907 [TBL] [Abstract][Full Text] [Related]
53. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748 [TBL] [Abstract][Full Text] [Related]
54. The promise of proprotein convertase subtilisin/kexin 9 inhibitors for the treatment of familial hypercholesterolemia. Pokharel Y; Virani SS; Ballantyne CM Curr Atheroscler Rep; 2015 May; 17(5):508. PubMed ID: 25782778 [TBL] [Abstract][Full Text] [Related]
55. PCSK9 Inhibitors May Show Benefits of Ultra-Low LDL Levels. Reinke T Manag Care; 2015 Aug; 24(8):13-4. PubMed ID: 26399135 [No Abstract] [Full Text] [Related]
57. Evolocumab (Repatha)--a second PCSK9 inhibitor to lower LDL-Cholesterol. Med Lett Drugs Ther; 2015 Oct; 57(1479):140-1. PubMed ID: 26445204 [TBL] [Abstract][Full Text] [Related]
58. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602 [TBL] [Abstract][Full Text] [Related]
60. PCSK9 Inhibitors: Are We on the Verge of a Breakthrough? Yang E Clin Pharmacol Ther; 2015 Dec; 98(6):590-601. PubMed ID: 26369501 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]